Published in AIDS Weekly, January 22nd, 2001
The new AmpligenR investigational protocol will be implemented side-by-side with another recently FDA authorized protocol (September 5, 2000) which is designed to suppress drug-resistant HIV after mutated virus has already appeared in a patient's blood stream.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.